The breast cancer suppressor proteins BRCA1 and BRCA2 interact with RAD51, a protein essential for maintaining genomic stability by playing a central role in homology-dependent recombinational repair of the DNA double-strand breaks. Therefore, genetic variability in the RAD51 gene may contribute to the appearance and/or progression of breast cancer. A single nucleotide polymorphism in the 5¢-untranslated region of RAD51 (a G to C substitution at position 135, the G/C polymorphism) is reported to modulate breast cancer risk. We investigated the distribution of genotypes and frequency of alleles of the G/C polymorphism in breast cancer. Tumor tissues were obtained from postmenopausal women with node-negative and node-positive breast carcinoma with uniform tumor size. Blood samples from age matched healthy women served as control. The G/C polymorphism was determined by PCR-based MvaI restriction fragment length polymorphism. The distribution of the genotypes of the G/C polymorphism did not differ significantly (P > 0.05) from those predicted by the Hardy-Weinberg distribution. There were no differences in the genotype distribution and allele frequencies between node-positive and node-negative patients. There were no significant differences between distributions of the genotypes in
subgroups assigned to histological grades according to Scarf-Bloom-Richardson criteria and the distribution predicted by Hardy-Weinberg equilibrium (P > 0.05). Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and/or progression of breast cancer and so it may not be useful as an independent marker in this disease.
Cancer is associated with genomic instability, which can be a consequence of many unrepaired DNA lesions. Therefore, malfunction of DNA repair can contribute to the instability and to cancer. This malfunction may follow from genetic variability, which could account for alterations of DNA repair proteins. Genetic factors are important in breast cancer and carriers of mutations in the BRCA1 and/or BRCA2 genes, whose products are involved in DNA repair, are of increased risk. The penetrance of these mutations can be modified by genetic factors including genes whose products can interact with BRCA1 and/or BRCA2 (Welcsh et al., 2000) . RAD51 is a homologue of bacterial RecA protein, which is required for meiotic and mitotic recombination and plays a central role in homology-dependent recombinational repair of DNA double-strand breaks. It is reported to interact with both BRCA1 and BRCA2 (Chen et al., 1998) . Therefore, the problem of genetic variability of the RAD51 gene in breast cancer is worth studying for at least two reasons: (1) the involvement of RAD51 in the stability of the genome and (2) its potential to modify the penetrance of BRCA1/BRCA2 mutations, which can increase susceptibility for breast cancer. A single nucleotide polymorphism in the 5¢-untranslated region (5¢-UTR) of RAD51 (a G to C substitution at position 135, the G/C polymorphism) can influence breast cancer risk among BRCA1/BRCA2 mutation carriers (Wang et al., 1999; Levy-Lahad et al., 2001) . About two thirds of all breast cancer patients are node-positive and usually receive adjuvant therapy, the other one third, which is node-negative, may or may not receive such therapy depending on the chance of disease recurrence (Kute et al., 1998) .
To explore further the association between the RAD51 G/C polymorphism and breast cancer risk we investigated the distribution of the genotypes and frequencies of alleles of this polymorphism in women with node-negative and node-positive breast cancer. We did not take into account the BRCA1/BRCA2 genotype of our patients because we wanted to check the potential of the polymorphism as an independent marker.
MATERIALS AND METHODS
Tumor tissues were obtained from 46 postmenopausal women with node-negative (n = 18) and node-positive (n = 28) ductal (n = 34) and non-ductal (n = 12) breast carcinoma treated in 2002 at the Department of Oncological Surgery, N. Copernicus Hospital (Lodz, Poland) . No distant metastases were found in the patients at the time of treatment. The patients ranged in age from 48 to 74 years (median age 63 years). The average tumor size was 20 mm (range 8-58 mm). All ductal tumors were graded by a method based on the criteria of Scarff-Bloom-Richardson. Steroid receptor status was not taken into account in this study. Blood samples from age matched healthy women (n = 60) served as control. Genomic DNA from tumor and blood samples was extracted by using standard phenolic procedure. RAD51 genotyping was analyzed by PCR amplification of a 175-bp region around nucleotide 135. This region contained a single MvaI site that was abolished in the 135C allele. Wild type alleles were digested by MvaI resulting in 86-and 71-bp products. The 135C allele was not digested by the enzyme, resulting in a single 157-bp product. PCR was performed in a MJ Research, INC thermal cycler, model PTC-100 by using the following primers: forward 5¢-TGG GAA CTG CAA CTC ATC TGG-3¢, reverse 5¢-GCG CTC CTC TCT CCA GCAG-3¢) at a final Mg concentration of 1.5 mM and an annealing temperature of 53°C. After digestion with MvaI for 4 h at 37°C, samples were run on 3% agarose gel. The allelic frequencies were estimated by gene counting and genotypes were scored. The observed numbers of each RAD51 genotype were compared with those expected for a population in Hardy-Weinberg equlibrium by using the c 2 test. The significance of the differences of the observed genotype distributions and allele frequencies between groups was tested using the c 2 analysis.
RESULTS AND DISCUSSION
From the PCR analysis, all the patients and controls were divided into three genotypes of the RAD51 5¢-UTR: C/C, G/C and G/G (Fig. 1 ). There were no differences in the genotype in tumor and normal tissue for each patient. Table 1 shows genotype distribution between breast cancer patients and controls. Both distributions did not differ significantly (P > 0.05) from those predicted by the Hardy-Weinberg distribution. Additionally there were no differences in the frequencies of the C and G alleles between patients and controls.
There were no significant differences between the G/C genotypes and the frequency of the C and G alleles for node-negative and node-positive breast cancer patients ( Table 2 ). The dependency of the distribution of the genotypes and frequencies of alleles on the tumor grade for ductal tumors evaluated according to Scarf-Bloom-Richardson criteria is displayed in Table 3 . Non-ductal tumors could not be classified by this criteria. There were no significant differences between the distributions of the genotypes in subgroups assigned to histological grades and the distribution predicted by Hardy-Weinberg equilibrium (P > 0.05). There were no differences in the frequencies of the C and G alleles between the subgroups either.
Our results suggest that the G/C polymorphism of the RAD51 5¢-UTR may not be linked with the appearance and progression of breast cancer. This polymorphism is reported to modify cancer risk in BRCA2 mutation carriers (Levy-Lahad et al., 2001; Wang et al., 2001) , but little is known about its potential general impact on breast cancer. The biological effect of the polymorphism is yet to be elucidated and will be important to investigate. As mentioned above, it is located in the 5¢-untranslated region of the RAD51 gene and could affect mRNA stability and/or translation efficiency, leading to altered product levels, which could affect the function of a multi-protein DNA-repair complex consisting of BRCA1, BRCA2 and RAD51. Because mutations in BRCA1 and BRCA2 are directly linked with breast cancer, genetic variations in the RAD51gene may be believed to play a role in this disease. Indeed, in breast cancer a loss of heterozygosity at the RAD51 locus has been reported in 32% (Gonzales et al., 1999) and reduced RAD51 protein levels in 30% of patients (Yoshikawa et al., 2000) . We tried to find a connection between breast cancer onset and the G/C polymorphism of the RAD51 Vol. 50 RAD51 polymorphism in breast cancer 251 gene without linkage with its other mutations and the results obtained suggest that this polymorphism may not be useful as an independent marker in breast cancer. However, our study had a preliminary character only and further research, performed on a larger group, is needed definitely to establish a correlation or lack thereof between breast cancer and the G/C polymorphism. 
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